Sutro Biopharma, a biopharmaceutical company developing antibody drug conjugates and bispecific antibodies, and the biopharmaceutical division of Merck KGaA, Darmstadt, Germany, which operates as EMD Serono in the United States and Canada, agreed to collaborate in the development of Antibody-drug Conjugates or ADCs.

The collaboration allows the biopharmaceutical division of Merck to take advantage of Sutro’sXpress CF™ and Xpress CF+™ platform technologies in its oncology programs to develop ADCs for a number of undisclosed targets, allowing the company to expands its oncology pipeline. Both companies believe that ADCs have the potential for directly targeting cancer cells while safeguarding healthy tissue and will combine Merck’s knowledge about target biology with Sutro’s technological and discovery capabilities to jointly develop ADCs. By following a strategic approach of creating partnerships, Merck and Sutro aim to develop drug candidates that may ultimately address the unmet needs of many cancer patients.

Published in: Sutro Biopharma, Inc and Merck KGaA/EMD Serono, Inc., websites

MabPlex